Genomics BioSci & Tech.Ltd（4195）株式概要Genomics BioSci & Tech.Ltd.は、台湾のゲノム関連企業です。 詳細4195 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析過去5年間で収益は年間47.6%減少しました。 TW市場と比較した過去 3 か月間の株価の変動意味のある時価総額がありません ( NT$1B )すべてのリスクチェックを見る4195 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueNT$Current PriceNT$18.8569.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-201m1b2016201920222025202620282031Revenue NT$1.2bEarnings NT$226.5mAdvancedSet Fair ValueView all narrativesGenomics BioSci & Tech. Co.,Ltd. 競合他社GenMont Biotech IncorporationSymbol: TWSE:3164Market cap: NT$1.4bUBI PharmaSymbol: TPEX:6562Market cap: NT$1.7bSynbio TechSymbol: TPEX:1295Market cap: NT$1.8bGenetics Generation AdvancementSymbol: TPEX:4160Market cap: NT$1.1b価格と性能株価の高値、安値、推移の概要Genomics BioSci & Tech.Ltd過去の株価現在の株価NT$18.8552週高値NT$36.8552週安値NT$17.90ベータ0.131ヶ月の変化-35.45%3ヶ月変化n/a1年変化1.34%3年間の変化-12.60%5年間の変化24.52%IPOからの変化-38.50%最新ニュースReported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.お知らせ • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan最新情報をもっと見るRecent updatesReported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.お知らせ • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwanお知らせ • Nov 11Genomics Has Announces New ResearchGenomics has announced new research that suggests polygenic risk scores (PRS) can significantly improve the predictive performance of the cardiovascular disease (CVD) risk prediction tool, PREVENT. The findings were presented at the American Heart Association Conference 2025. The research shows that adding genetic risk to CVD tools can better identify individuals at risk of heart disease, with this benefit seen across ancestries. The findings support the implementation of PRS with the next generation of clinical CVD risk predictors, adding to a growing body of evidence that PRS can help improve CVD prevention, saving patient lives and improving population health. CVD is the leading cause of death in the U.S., claiming over 900,000 lives in 2023, accounting for approximately one in three deaths. There is one CVD death every 34 seconds, and someone has a heart attack every 40 seconds. The cost of heart disease in the U.S. in 2024 was over $400 billion. The key to CVD prevention is to identify people at high risk of the disease and to reduce their risk through statin therapy and lifestyle changes. The widespread use of statins for CVD prevention earlier this century has dramatically reduced CVD deaths. A meta-analysis of 25 trials involving nearly 70,000 patients with coronary heart disease found that the use of statins reduces CVD events by 25% and overall mortality by 16%. Previous studies had shown that adding polygenic risk to earlier clinical risk calculators significantly improves risk prediction for CVD. Further, 8% of individuals aged 40-69 were reclassified as higher risk in the IRT compared to PREVENT alone. These high-risk individuals are not currently flagged by PREVENT. Using these calculations, the researchers also found that over three million people aged 40-70 in the U.S. at high risk of CVD are currently invisible to the system, because genetics is not being used as part of CVD risk prediction measures. Statins are even more effective than average for people with high PRS. This means that over 100,000 people could avoid CVD-related complications over ten years if PRS were routinely added to PREVENT, followed by statin treatment for the newly classified high-risk individuals (compared to these individuals not being treated with statins). This study adds to a growing body of data that PRS can help improveCVD management and prevention. Genomics's 2021 HEART clinical trial, conducted with the United Kingdom's National Health Service (NHS), demonstrated that integrating genetic data into cardiovascular risk assessments fitted smoothly into clinical care pathways and changed patient management. The recently released 10-year plan for the NHS committed to rolling out prevention based on PRS to the whole country.New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$264m free cash flow). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$2.03b market cap, or US$67.1m).お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city TaiwanNew Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-NT$289m). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.39b market cap, or US$42.4m).Reported Earnings • Apr 16Full year 2023 earnings released: NT$2.36 loss per share (vs NT$1.13 profit in FY 2022)Full year 2023 results: NT$2.36 loss per share (down from NT$1.13 profit in FY 2022). Revenue: NT$396.1m (down 5.5% from FY 2022). Net loss: NT$168.1m (down 335% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.お知らせ • Mar 22Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024.New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.44b market cap, or US$45.6m).Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$25.70, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 44x in the Biotechs industry in Taiwan. Total returns to shareholders of 4.0% over the past three years.Reported Earnings • Apr 26Full year 2022 earnings released: EPS: NT$1.15 (vs NT$0.32 in FY 2021)Full year 2022 results: EPS: NT$1.15 (up from NT$0.32 in FY 2021). Revenue: NT$419.0m (up 7.4% from FY 2021). Net income: NT$71.6m (up 282% from FY 2021). Profit margin: 17% (up from 4.8% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 100% share price gain to NT$20.30, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 190% over the past three years.Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$1.13 (vs NT$0.71 in 1H 2021)First half 2022 results: EPS: NT$1.13 (up from NT$0.71 in 1H 2021). Revenue: NT$205.2m (up 6.4% from 1H 2021). Net income: NT$67.9m (up 64% from 1H 2021). Profit margin: 33% (up from 21% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.Reported Earnings • Apr 27Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.011 in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.011 in FY 2020). Revenue: NT$390.0m (down 12% from FY 2020). Net income: NT$18.7m (up NT$18.1m from FY 2020). Profit margin: 4.8% (up from 0.1% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022.Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$16.95, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 20x in the Biotechs industry in Taiwan. Total returns to shareholders of 21% over the past three years.Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$0.71 (vs NT$0.027 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: NT$192.9m (down 8.3% from 1H 2020). Net income: NT$41.3m (up NT$42.9m from 1H 2020). Profit margin: 21% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 28Full year 2020 earnings released: EPS NT$0.01 (vs NT$0.31 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$443.2m (up 3.6% from FY 2019). Net income: NT$619.0k (down 97% from FY 2019). Profit margin: 0.1% (down from 4.2% in FY 2019). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.分析記事 • Apr 27Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?Is Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...お知らせ • Mar 11Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021.Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$18.45, the stock is trading at a trailing P/E ratio of 77.6x, up from the previous P/E ratio of 65.2x. This compares to an average P/E of 40x in the Biotechs industry in Taiwan. Total return to shareholders over the past three years is a loss of 19%.Is New 90 Day High Low • Jan 28New 90-day low: NT$16.50The company is down 6.0% from its price of NT$17.60 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.分析記事 • Jan 19Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its DividendIs Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...分析記事 • Nov 25Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Genomics BioSci & Tech.Ltd (GTSM:4195) has had a great run on the share market with its stock up by a significant 12...Is New 90 Day High Low • Nov 24New 90-day high: NT$19.50The company is up 8.0% from its price of NT$18.00 on 26 August 2020. The Taiwanese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 1.0% over the same period.株主還元4195TW BiotechsTW 市場7D1.1%-1.3%2.6%1Y1.3%28.2%94.7%株主還元を見る業界別リターン: 4195過去 1 年間で28.2 % の収益を上げたTW Biotechs業界を下回りました。リターン対市場: 4195は、過去 1 年間で94.7 % のリターンを上げたTW市場を下回りました。価格変動Is 4195's price volatile compared to industry and market?4195 volatility4195 Average Weekly Movement10.7%Biotechs Industry Average Movement6.0%Market Average Movement6.2%10% most volatile stocks in TW Market12.2%10% least volatile stocks in TW Market2.5%安定した株価: 4195の株価は、 TW市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 4195の weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてTWの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2001n/aRita Wuwww.genomics.com.twGenomics BioSci & Tech Ltd.は台湾でゲノム関連事業を展開。シーケンシング、合成、ゲノム、プロテオミクス、代理店・販売サービス、生殖医療・がん検査サービス、受託開発・製造サービスを提供。Genomics BioSci & Tech Ltd.は2001年に設立され、台湾の新北市に拠点を置く。もっと見るGenomics BioSci & Tech. Co.,Ltd. 基礎のまとめGenomics BioSci & Tech.Ltd の収益と売上を時価総額と比較するとどうか。4195 基礎統計学時価総額NT$1.37b収益（TTM）-NT$54.09m売上高(TTM)NT$738.40m1.8xP/Sレシオ-25.2xPER（株価収益率4195 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計4195 損益計算書（TTM）収益NT$738.40m売上原価NT$498.77m売上総利益NT$239.63mその他の費用NT$293.72m収益-NT$54.09m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.75グロス・マージン32.45%純利益率-7.33%有利子負債／自己資本比率117.2%4195 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 10:10終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genomics BioSci & Tech. Co.,Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Jianzheng WuCapital Securities Corporation
Reported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).
Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25
お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan
Reported Earnings • May 19First quarter 2026 earnings released: NT$0.54 loss per share (vs NT$0.34 loss in 1Q 2025)First quarter 2026 results: NT$0.54 loss per share (further deteriorated from NT$0.34 loss in 1Q 2025). Revenue: NT$151.8m (up 25% from 1Q 2025). Net loss: NT$39.1m (loss widened 60% from 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year.
お知らせ • May 13Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million.Genomics BioSci & Tech. Co.,Ltd. has completed a Follow-on Equity Offering in the amount of TWD 166.89322 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,437,000 Price\Range: TWD 22.06 Security Name: Shares Security Type: Common Stock Securities Offered: 2,115,000 Price\Range: TWD 22.2
New Risk • May 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 53% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (NT$1.62b market cap, or US$51.4m).
Reported Earnings • Apr 07Full year 2025 earnings released: NT$0.54 loss per share (vs NT$3.08 loss in FY 2024)Full year 2025 results: NT$0.54 loss per share (improved from NT$3.08 loss in FY 2024). Revenue: NT$708.4m (up 47% from FY 2024). Net loss: NT$39.4m (loss narrowed 82% from FY 2024). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings.
お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million.Genomics BioSci & Tech. Co.,Ltd. has filed a Follow-on Equity Offering in the amount of TWD 0.1888 million. Security Name: Shares Security Type: Common Stock Securities Offered: 7,552 Price(maximum): TWD 25
お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 26, 2026. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan
お知らせ • Nov 11Genomics Has Announces New ResearchGenomics has announced new research that suggests polygenic risk scores (PRS) can significantly improve the predictive performance of the cardiovascular disease (CVD) risk prediction tool, PREVENT. The findings were presented at the American Heart Association Conference 2025. The research shows that adding genetic risk to CVD tools can better identify individuals at risk of heart disease, with this benefit seen across ancestries. The findings support the implementation of PRS with the next generation of clinical CVD risk predictors, adding to a growing body of evidence that PRS can help improve CVD prevention, saving patient lives and improving population health. CVD is the leading cause of death in the U.S., claiming over 900,000 lives in 2023, accounting for approximately one in three deaths. There is one CVD death every 34 seconds, and someone has a heart attack every 40 seconds. The cost of heart disease in the U.S. in 2024 was over $400 billion. The key to CVD prevention is to identify people at high risk of the disease and to reduce their risk through statin therapy and lifestyle changes. The widespread use of statins for CVD prevention earlier this century has dramatically reduced CVD deaths. A meta-analysis of 25 trials involving nearly 70,000 patients with coronary heart disease found that the use of statins reduces CVD events by 25% and overall mortality by 16%. Previous studies had shown that adding polygenic risk to earlier clinical risk calculators significantly improves risk prediction for CVD. Further, 8% of individuals aged 40-69 were reclassified as higher risk in the IRT compared to PREVENT alone. These high-risk individuals are not currently flagged by PREVENT. Using these calculations, the researchers also found that over three million people aged 40-70 in the U.S. at high risk of CVD are currently invisible to the system, because genetics is not being used as part of CVD risk prediction measures. Statins are even more effective than average for people with high PRS. This means that over 100,000 people could avoid CVD-related complications over ten years if PRS were routinely added to PREVENT, followed by statin treatment for the newly classified high-risk individuals (compared to these individuals not being treated with statins). This study adds to a growing body of data that PRS can help improveCVD management and prevention. Genomics's 2021 HEART clinical trial, conducted with the United Kingdom's National Health Service (NHS), demonstrated that integrating genetic data into cardiovascular risk assessments fitted smoothly into clinical care pathways and changed patient management. The recently released 10-year plan for the NHS committed to rolling out prevention based on PRS to the whole country.
New Risk • Sep 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-NT$264m free cash flow). Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (NT$2.03b market cap, or US$67.1m).
お知らせ • Mar 17Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 20, 2025. Location: no,237-6, sec.1 ta t`ung rd., sijhih district, new taipei city Taiwan
New Risk • Feb 25New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 55% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-NT$289m). Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (NT$1.39b market cap, or US$42.4m).
Reported Earnings • Apr 16Full year 2023 earnings released: NT$2.36 loss per share (vs NT$1.13 profit in FY 2022)Full year 2023 results: NT$2.36 loss per share (down from NT$1.13 profit in FY 2022). Revenue: NT$396.1m (down 5.5% from FY 2022). Net loss: NT$168.1m (down 335% from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance.
お知らせ • Mar 22Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 12, 2024.
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (NT$1.44b market cap, or US$45.6m).
Upcoming Dividend • Aug 01Upcoming dividend of NT$0.10 per share at 0.4% yieldEligible shareholders must have bought the stock before 08 August 2023. Payment date: 08 September 2023. Payout ratio is a comfortable 8.7% but the company is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of Taiwanese dividend payers (5.4%). Lower than average of industry peers (2.8%).
Valuation Update With 7 Day Price Move • Jun 07Investor sentiment improves as stock rises 17%After last week's 17% share price gain to NT$25.70, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 44x in the Biotechs industry in Taiwan. Total returns to shareholders of 4.0% over the past three years.
Reported Earnings • Apr 26Full year 2022 earnings released: EPS: NT$1.15 (vs NT$0.32 in FY 2021)Full year 2022 results: EPS: NT$1.15 (up from NT$0.32 in FY 2021). Revenue: NT$419.0m (up 7.4% from FY 2021). Net income: NT$71.6m (up 282% from FY 2021). Profit margin: 17% (up from 4.8% in FY 2021). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 100% share price gain to NT$20.30, the stock trades at a trailing P/E ratio of 55.3x. Average trailing P/E is 42x in the Biotechs industry in Taiwan. Total returns to shareholders of 190% over the past three years.
Reported Earnings • Aug 15First half 2022 earnings released: EPS: NT$1.13 (vs NT$0.71 in 1H 2021)First half 2022 results: EPS: NT$1.13 (up from NT$0.71 in 1H 2021). Revenue: NT$205.2m (up 6.4% from 1H 2021). Net income: NT$67.9m (up 64% from 1H 2021). Profit margin: 33% (up from 21% in 1H 2021). Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
Reported Earnings • Apr 27Full year 2021 earnings released: EPS: NT$0.32 (vs NT$0.011 in FY 2020)Full year 2021 results: EPS: NT$0.32 (up from NT$0.011 in FY 2020). Revenue: NT$390.0m (down 12% from FY 2020). Net income: NT$18.7m (up NT$18.1m from FY 2020). Profit margin: 4.8% (up from 0.1% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 100% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 02Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, Jun 24, 2022.
Valuation Update With 7 Day Price Move • Oct 19Investor sentiment improved over the past weekAfter last week's 18% share price gain to NT$16.95, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 20x in the Biotechs industry in Taiwan. Total returns to shareholders of 21% over the past three years.
Reported Earnings • Aug 18First half 2021 earnings released: EPS NT$0.71 (vs NT$0.027 loss in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: NT$192.9m (down 8.3% from 1H 2020). Net income: NT$41.3m (up NT$42.9m from 1H 2020). Profit margin: 21% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 28Full year 2020 earnings released: EPS NT$0.01 (vs NT$0.31 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: NT$443.2m (up 3.6% from FY 2019). Net income: NT$619.0k (down 97% from FY 2019). Profit margin: 0.1% (down from 4.2% in FY 2019). Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
分析記事 • Apr 27Is Genomics BioSci & Tech. Co.,Ltd.'s (GTSM:4195) 7.2% Dividend Worth Your Time?Is Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...
お知らせ • Mar 11Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021Genomics BioSci & Tech. Co.,Ltd., Annual General Meeting, May 28, 2021.
Valuation Update With 7 Day Price Move • Feb 23Investor sentiment improved over the past weekAfter last week's 19% share price gain to NT$18.45, the stock is trading at a trailing P/E ratio of 77.6x, up from the previous P/E ratio of 65.2x. This compares to an average P/E of 40x in the Biotechs industry in Taiwan. Total return to shareholders over the past three years is a loss of 19%.
Is New 90 Day High Low • Jan 28New 90-day low: NT$16.50The company is down 6.0% from its price of NT$17.60 on 30 October 2020. The Taiwanese market is up 23% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period.
分析記事 • Jan 19Key Things To Consider Before Buying Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) For Its DividendIs Genomics BioSci & Tech. Co.,Ltd. ( GTSM:4195 ) a good dividend stock? How can we tell? Dividend paying companies...
分析記事 • Nov 25Genomics BioSci & Tech. Co.,Ltd. (GTSM:4195) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?Genomics BioSci & Tech.Ltd (GTSM:4195) has had a great run on the share market with its stock up by a significant 12...
Is New 90 Day High Low • Nov 24New 90-day high: NT$19.50The company is up 8.0% from its price of NT$18.00 on 26 August 2020. The Taiwanese market is also up 8.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Biotechs industry, which is down 1.0% over the same period.
